Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency.
Switching from daily GH to once-weekly somapacitan showed no significant difference in total lean mass but did improve some functional outcomes.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study measured metabolic and functional outcomes in adults with growth hormone deficiency who switched from daily somatropin to once-weekly somapacitan. The primary endpoint showed no significant difference in total lean mass change after 52 weeks. Exploratory analyses indicated some improvements in physical performance metrics.
Abstract
Context Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains unclear. Objective To compare the metabolic and functional outcomes in patients who switched from daily GH to somapacitan with those who continued daily GH. Methods Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks.This study was conducted at a single-center providing routine endocrine management.Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH.Switching from daily GH to once-weekly somapacitan, or continuing daily treatment based on patient preference.The prespecified primary endpoint was the dual-energy X-ray absorptiometry-derived change in total lean mass from baseline to week 52. Exploratory endpoints included body composition, lipid profile, and physical performance. Results Baseline and week 52 insulin-like growth factor 1 standard deviation scores distributions were similar between the groups; yet the increase was greater with daily GH than with somapacitan. The primary endpoint showed no between-group difference (mean difference -0.2 kg; 95% CI -1.5 to 1.1). Somapacitan was associated with increased adiposity indices, yet it improved high-density lipoprotein-cholesterol. Exploratory analyses revealed improvements in handgrip strength and Timed Up and Go Test. No new safety concerns were observed. Conclusion In routine practice, switching to once-weekly somapacitan was associated with improved functional outcomes, despite less favorable adiposity trajectories, compared with daily therapy. Further studies are required to clarify long-term effects.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.